TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15060437

Group type: EXPERIMENTAL
Intervention: GW433908 1395 mg QD + RTV 200 mg QD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GW433908 700 mg BID + RTV 100 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GW433908 1395 mg QD + RTV 300 mg QD
Number of subjects: 0

Group type: COMPARATOR
Intervention: EFV 600 mg QD with GW433908 + RTV regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: EFV 600 mg QD with GW433908 1395 mg QD + RTV 200 mg QD
Number of subjects: 0
Study: 11666098

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 15
Study: 9495407

Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine
Number of subjects: 51

Group type: COMPARATOR
Intervention: 0.125% bupivacaine
Number of subjects: 51
Study: 8834668

Group type: EXPERIMENTAL
Intervention: Low-dose antacids (bismuth subnitrate - Gastrin and Wikalina)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 2642979

Group type: EXPERIMENTAL
Intervention: Test meal (710 kcal)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous glucagon (40 micrograms/min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous vasopressin (0.2 units/min)
Number of subjects: 9
Study: 1103919

Group type: EXPERIMENTAL
Intervention: Benzoctamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine (in animal experiments)
Number of subjects: 0
Study: 31811456

Group type: EXPERIMENTAL
Intervention: 3-D/HD monitor
Number of subjects: 66

Group type: COMPARATOR
Intervention: 2-D/4K monitor
Number of subjects: 66

Group type: COMPARATOR
Intervention: 2-D/HD monitor
Number of subjects: 66
Study: 30570198

Group type: EXPERIMENTAL
Intervention: Team Based Learning (TBL) on 'organ function tests'
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional lecture on 'organ function tests'
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Team Based Learning (TBL)
Number of subjects: 100
Study: 27320010

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 87
Study: 25998278

Group type: EXPERIMENTAL
Intervention: Enhanced supported employment plus the Thinking Skills for Work program
Number of subjects: 107

Group type: COMPARATOR
Intervention: Enhanced supported employment only
Number of subjects: 107
Study: 24830730

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 24
Study: 22005659

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Dexamethasone (all doses)
Number of subjects: 98
Study: 18356831

Group type: EXPERIMENTAL
Intervention: Tesofensine 0.125 mg
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Tesofensine 0.25 mg
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Tesofensine 0.5 mg
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Tesofensine 1.0 mg
Number of subjects: 968

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Tesofensine (all doses combined)
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Tesofensine (0.25 mg and above)
Number of subjects: 968
Study: 17349164

Group type: EXPERIMENTAL
Intervention: i.v group
Number of subjects: 88

Group type: COMPARATOR
Intervention: i.m group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: domino group
Number of subjects: 88
Study: 12900815

Group type: EXPERIMENTAL
Intervention: Oral heme iron
Number of subjects: 37
Study: 10698808

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 9216958

Group type: EXPERIMENTAL
Intervention: Tr (trained)
Number of subjects: 22

Group type: COMPARATOR
Intervention: UT (untrained)
Number of subjects: 22
Study: 8153036

Group type: EXPERIMENTAL
Intervention: Educational training program combining self-management training and cognitive behaviour therapy; ten 1-hour sessions over 18 months.
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control groups (two control groups); no specific intervention details provided.
Number of subjects: 112
Study: 2869638

Group type: EXPERIMENTAL
Intervention: Soft gelatin capsule of temazepam 20 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tablet of temazepam 20 mg
Number of subjects: 60
Study: 30409178

Group type: EXPERIMENTAL
Intervention: Middle turbinectomy
Number of subjects: 16
Study: 27339057

Group type: EXPERIMENTAL
Intervention: Combination therapy with fractional Er:YAG laser and 5% amorolfine lacquer (group 1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Amorolfine lacquer only (group 2)
Number of subjects: 9
Study: 24943856

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 23156940

Group type: EXPERIMENTAL
Intervention: Rhythmic Movement Therapy (RMT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 58
Study: 20386330

Group type: EXPERIMENTAL
Intervention: Soap and water washing
Number of subjects: 45

Group type: COMPARATOR
Intervention: No-rinse cleanser
Number of subjects: 45
Study: 18271231

Group type: EXPERIMENTAL
Intervention: Acupuncture at Xuanzhong (GB 39) and Ashi points for 30 minutes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bezoxazocine injection, 20 mg once, three times per day
Number of subjects: 60
Study: 15494707

Group type: EXPERIMENTAL
Intervention: Hyperprolinemia
Number of subjects: 434
Study: 11991284

Group type: EXPERIMENTAL
Intervention: Low-dose local nasal immunotherapy (LNIT) with a build-up phase from 2.5 AU to 80 AU and maintenance at 80 AU once a week
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10209659

Group type: EXPERIMENTAL
Intervention: Group psychological treatment (education, relaxation, breathing training, graded exposure to activity and exercise, challenging automatic thoughts about heart disease)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group psychological treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 60
Study: 8531509

Group type: EXPERIMENTAL
Intervention: 16 mg DL-oxyfedrine*HCl tablets
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 96 mg DL-oxyfedrine*HCl tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Equimolar aqueous solution of DL-oxyfedrine*HCl
Number of subjects: 12
Study: 2625270

Group type: EXPERIMENTAL
Intervention: Marked group (140 patients) - lymphatic tissue of the axilla marked by technetium‐99 antimonsulfide and operated on a gammacamera
Number of subjects: 264

Group type: COMPARATOR
Intervention: Unmarked group (124 patients) - no marking of lymphatic tissue
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 264
Study: 29720097

Group type: EXPERIMENTAL
Intervention: Progressively autonomous physical activity (PAPA) program
Number of subjects: 47

Group type: COMPARATOR
Intervention: Supervised physical activity (SPA) program
Number of subjects: 47
Study: 26272050

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 97
Study: 26240500

Group type: EXPERIMENTAL
Intervention: Ideal body weight
Number of subjects: 100

Group type: COMPARATOR
Intervention: Actual body weight
Number of subjects: 100
Study: 23471549

Group type: EXPERIMENTAL
Intervention: rFSH + letrozole (2.5 mg on days 3-7 of the menstrual cycle)
Number of subjects: 40

Group type: COMPARATOR
Intervention: rFSH alone (starting on day 3)
Number of subjects: 40
Study: 21029314

Group type: EXPERIMENTAL
Intervention: Intravesical thermochemotherapy (Synergo®)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Intravesical chemotherapy alone (mitomycin-C)
Number of subjects: 83
Study: 19441888

Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol
Number of subjects: 232

Group type: COMPARATOR
Intervention: Timolol alone
Number of subjects: 232
Study: 16571908

Group type: EXPERIMENTAL
Intervention: Event-related functional MRI (fMRI)
Number of subjects: 0
Study: 14616151

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 717

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study: 10890540

Group type: EXPERIMENTAL
Intervention: Lithotripsy (maximum of 4 sessions, up to 3000 shocks/session, no anaesthesia or analgesia)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Cholecystectomy (elective open under general anaesthesia)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Crossover group (patients who underwent cholecystectomy after lithotripsy)
Number of subjects: 144
Study: 9314638

Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 103

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 103
Study: 8375130

Group type: EXPERIMENTAL
Intervention: 75 mg desipramine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 225 mg fluvoxamine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 450 mg moclobemide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3522157

Group type: EXPERIMENTAL
Intervention: Brodimoprim (400 mg loading dose followed by 200 mg for 10 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Doxycycline (200 mg loading dose followed by 100 mg for 10 days)
Number of subjects: 60
Study: 28960257

Group type: EXPERIMENTAL
Intervention: Growth mindset intervention (n = 115)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Attention-matched control programme (n = 107)
Number of subjects: 222
Study: 27552274

Group type: EXPERIMENTAL
Intervention: Community Engagement Program (CEP)
Number of subjects: 595

Group type: COMPARATOR
Intervention: Technical Assistance (Resources for Services, RS)
Number of subjects: 595
Study: 25011605

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) for 5 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: North American isoenergetic control diet for 5 weeks
Number of subjects: 26
Study: 22203318

Group type: EXPERIMENTAL
Intervention: Mindfulness-oriented therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addiction support group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcohol-dependent patients who relapsed
Number of subjects: 0
Study: 20691832

Group type: EXPERIMENTAL
Intervention: Pexelizumab treatment
Number of subjects: 64
Study: 18294109

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg administered as a 2-minute intravenous bolus injection
Number of subjects: 38

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg administered as a 30-minute continuous infusion
Number of subjects: 38

Group type: COMPARATOR
Intervention: Normal saline (placebo) administered as an intravenous injection over 2 minutes
Number of subjects: 38
Study: 17138081

Group type: EXPERIMENTAL
Intervention: Allon ThermoWrapping Thermoregulation System (study group, n = 15)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Forced-air system (Bair Hugger, control group, n = 16)
Number of subjects: 31
Study: 12626998

Group type: EXPERIMENTAL
Intervention: Prostacyclin (5 ng x kg(‐1) x min(‐1)) plus unfractionated heparin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prostacyclin plus unfractionated heparin
Number of subjects: 24
Study: 11076347

Group type: EXPERIMENTAL
Intervention: Short-term topical steroid therapy (6 months)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Long-term topical steroid therapy (12 months)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Systemic and local steroids treatment
Number of subjects: 207
Study: 9299905

Group type: EXPERIMENTAL
Intervention: Shock anticipation (threat-of-shock experiment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention to external stimuli (control experiment)
Number of subjects: 0
Study: 8382824

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tibenelast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3539033

Group type: EXPERIMENTAL
Intervention: Topical anaesthetic cream
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31759938

Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg every 2 weeks for 6 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Lipoprotein apheresis (LA)
Number of subjects: 39
Study: 26777257

Group type: EXPERIMENTAL
Intervention: Multimode Comprehensive Tailored Information Package (MCTIP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ad hoc information provision (Control)
Number of subjects: 31
Study: 25692612

Group type: EXPERIMENTAL
Intervention: Prolonged bivalirudin infusion
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard bivalirudin treatment
Number of subjects: 160
Study: 23831264

Group type: EXPERIMENTAL
Intervention: Spironolactone (300mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21992961

Group type: EXPERIMENTAL
Intervention: CS with bladder flap formation (BFF)
Number of subjects: 115

Group type: COMPARATOR
Intervention: CS without bladder flap formation (BFF)
Number of subjects: 115
Study: 19347349

Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (macula hole or membrane)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CRVO
Number of subjects: 12
Study: 16762754

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine (LDD)
Number of subjects: 41
Study: 15245597

Group type: EXPERIMENTAL
Intervention: Daily intake of 9 capsules of green tea extract powder per day (equivalent to 10 cups of regular green tea) for 5 months
Number of subjects: 83

Group type: COMPARATOR
Intervention: No intake of green tea capsules (control group)
Number of subjects: 83
Study: 11688594

Group type: EXPERIMENTAL
Intervention: Estradiol and progesterone replacement therapy for 6 weeks postnatally
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated infants (controls)
Number of subjects: 30
Study: 9136939

Group type: EXPERIMENTAL
Intervention: melphalan/prednisone + interferon alpha‐2b
Number of subjects: 0

Group type: COMPARATOR
Intervention: melphalan/prednisone
Number of subjects: 0
Study: 8226554

Group type: EXPERIMENTAL
Intervention: Air with dead space (AVD)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 100% O2 with dead space (O2VD)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Air control (AC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 100% O2 control (O2C)
Number of subjects: 9
Study: 3693764

Group type: EXPERIMENTAL
Intervention: Maternal exclusion diet (cow's milk and egg)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Nondiet (control group)
Number of subjects: 212
Study: 29713403

Group type: EXPERIMENTAL
Intervention: Gluteal trigger point injections with prilocaine, home exercise program, and oral medications
Number of subjects: 65

Group type: COMPARATOR
Intervention: Home exercise program and oral medications
Number of subjects: 65
Study: 27320846

Group type: EXPERIMENTAL
Intervention: Green tea polyphenols (GTP) containing 800 mg of epigallocatechin gallate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 25469706

Group type: EXPERIMENTAL
Intervention: Unilateral STN DBS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Unilateral GPi DBS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combined STN and GPi groups
Number of subjects: 30
Study: 22650140

Group type: EXPERIMENTAL
Intervention: New percutaneous absorption herbal patch
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Traditional medicinal herbs cake
Number of subjects: 120

Group type: COMPARATOR
Intervention: Western medication (Accuhaler)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Medicine patch and medicinal vesiculation groups
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Medicine patch group
Number of subjects: 120
Study: 20148791

Group type: EXPERIMENTAL
Intervention: Internet-based prevention programme (Climate Schools: Alcohol and Cannabis Course)
Number of subjects: 764

Group type: COMPARATOR
Intervention: Usual health classes (Control group)
Number of subjects: 764
Study: 18276061

Group type: EXPERIMENTAL
Intervention: Bevacizumab (10mg/kg) and Docetaxel (60mg/m²) every 3 weeks
Number of subjects: 20
Study: 16509282

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler sonography on day 1 of the menstrual cycle
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler sonography on day 15 of the menstrual cycle
Number of subjects: 40
Study: 12445591

Group type: EXPERIMENTAL
Intervention: Prevention videotape on dieting and body image (n = 104)
Number of subjects: 218

Group type: COMPARATOR
Intervention: No intervention (control group, n = 114)
Number of subjects: 218
Study: 10850304

Group type: EXPERIMENTAL
Intervention: Whole Tumor (WT) vaccine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: TC vaccine (derived from IIB-MEL-J cells)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No immunotherapy (control group)
Number of subjects: 28
Study: 8789216

Group type: EXPERIMENTAL
Intervention: Occlusive glove on normal skin 6 h/day for 3 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Occlusive glove on SLS-compromised skin 6 h/day for 3 days
Number of subjects: 40
Study: 2018207

Group type: EXPERIMENTAL
Intervention: Breathing 100% O2 during MCH challenge
Number of subjects: 19

Group type: COMPARATOR
Intervention: Breathing 21% O2 during MCH challenge
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Asthmatic patients breathing 100% O2 during MCH challenge
Number of subjects: 19

Group type: COMPARATOR
Intervention: Asthmatic patients breathing 21% O2 during MCH challenge
Number of subjects: 19
Study: 7178914

Group type: EXPERIMENTAL
Intervention: Activation program for elderly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30554748

Group type: EXPERIMENTAL
Intervention: CRP group A (threshold of 20 mg/L)
Number of subjects: 2410

Group type: EXPERIMENTAL
Intervention: CRP group B (threshold of 40 mg/L)
Number of subjects: 2410

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2410

Group type: EXPERIMENTAL
Intervention: CRP group B vs control group
Number of subjects: 2410

Group type: EXPERIMENTAL
Intervention: CRP group A vs control group
Number of subjects: 2410

Group type: EXPERIMENTAL
Intervention: CRP group A (CRP <20 mg/L)
Number of subjects: 2410

Group type: EXPERIMENTAL
Intervention: CRP group B (CRP <40 mg/L)
Number of subjects: 2410
Study: 30562293

Group type: EXPERIMENTAL
Intervention: Self-administered 3-item questionnaire (3IQ)
Number of subjects: 227

Group type: COMPARATOR
Intervention: No change to wait-list priority (Control)
Number of subjects: 227
Study: 26752586

Group type: EXPERIMENTAL
Intervention: Head Start REDI intervention
Number of subjects: 356

Group type: COMPARATOR
Intervention: Head Start as usual (control)
Number of subjects: 356
Study: 24132660

Group type: EXPERIMENTAL
Intervention: CHO/fibre diet
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MUFA diet
Number of subjects: 45

Group type: COMPARATOR
Intervention: Supervised low-volume aerobic training
Number of subjects: 45
Study: 22344554

Group type: EXPERIMENTAL
Intervention: Rapidly dissolving levetiracetam minitablets (1000 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rapidly dissolving levetiracetam minitablets (1500 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Single-unit film-coated originator tablets (1000 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Single-unit film-coated originator tablets (1500 mg)
Number of subjects: 16
Study: 20171332

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy for Binge Eating Disorder (DBT‐BED)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Active Comparison Group Therapy (ACGT)
Number of subjects: 101
Study: 16895621

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen 15 mg kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intramuscular meperidine 1 mg kg‐1
Number of subjects: 40
Study: 16376774

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Neurologic impairment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Renal impairment
Number of subjects: 45
Study: 12461475

Group type: EXPERIMENTAL
Intervention: Lycasin HBC
Number of subjects: 12

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 12
Study: 10522990

Group type: EXPERIMENTAL
Intervention: 0.5 mg aldosterone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.05 mg aldosterone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7747707

Group type: EXPERIMENTAL
Intervention: TAE plus UFT (tegafur 200 mg and uracil 448 mg per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: TAE alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TAE plus UFT
Number of subjects: 40
Study: 1674230

Group type: EXPERIMENTAL
Intervention: roxatidine acetate hydrochloride 75 mg at 9 PM
Number of subjects: 192

Group type: COMPARATOR
Intervention: untreated control group
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: roxatidine acetate hydrochloride
Number of subjects: 192
Study: 7352689

Group type: EXPERIMENTAL
Intervention: Cinnarizine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30867551

Group type: EXPERIMENTAL
Intervention: Intranasal naloxone (2 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intranasal naloxone (4 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intranasal naloxone (2 mg and 4 mg)
Number of subjects: 14
Study: 28083711

Group type: EXPERIMENTAL
Intervention: Imatinib treatment (first-line)
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Transcript type e13a2
Number of subjects: 1494